Skip to main content

REVIEW article

Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2024 | doi: 10.3389/fimmu.2024.1516419
This article is part of the Research Topic Antibody-drug Conjugates in Solid and Hematologic Malignancies View all 3 articles

Antibody-Drug Conjugates in Cancer Therapy: Applications and Future Advances

Provisionally accepted
R L R L *GY T GY T *CH Z CH Z *XR Y XR Y *JS L JS L *XY L XY L *YQ D YQ D *JY Q JY Q *JL L JL L *Jianhong Zuo Jianhong Zuo *
  • University of South China, Hengyang, China

The final, formatted version of the article will be published soon.

    Antibody-Drug Conjugates (ADCs) represent an emerging cancer therapeutic strategy and are becoming increasingly significant in the field of public health. With the evolution of precision oncology, the potential applications of ADCs are being realized more broadly.This review provides an overview of the fundamental molecular design of ADCs, examining how each component-antibody, linker, payload, and coupling chemistry-affects the physicochemical and biological properties of the final product. The paper also discusses novel ADC designs that are in preclinical and early clinical development stages as next-generation cancer therapies. These include bispecific ADCs, Probody drug conjugate, immunostimulatory ADCs (ISACs), Degrader-Antibody Conjugates (DACs), and Dual-Payload ADCs. Their applications and potential future advancements in cancer therapy are also explored.

    Keywords: Antibody-drug conjugates, ADCS, Linker, Probody drug conjugate,, Dual-Payload ADCs

    Received: 24 Oct 2024; Accepted: 31 Dec 2024.

    Copyright: © 2024 L, T, Z, Y, L, L, D, Q, L and Zuo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    R L, University of South China, Hengyang, China
    GY T, University of South China, Hengyang, China
    CH Z, University of South China, Hengyang, China
    XR Y, University of South China, Hengyang, China
    JS L, University of South China, Hengyang, China
    XY L, University of South China, Hengyang, China
    YQ D, University of South China, Hengyang, China
    JY Q, University of South China, Hengyang, China
    JL L, University of South China, Hengyang, China
    Jianhong Zuo, University of South China, Hengyang, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.